Healthcare / Medical DevicesSES
$0.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $1.1M · quality 44.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$13M
P/E
N/A
•EV/EBITDA
N/A
•ROE
180.0%
↑Gross Margin
45.4%
↓Debt/Equity
-2.74
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.7%
FCF CAGR
—
FCF margin
14.5%
FCF / Net income
-0.69x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $13.1M · net income $-2.7M · FCF $1.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $13.1M | $13.1M | $12.7M | $13.1M | $9.4M |
| Net Income | $-2.7M | $-2.7M | $-2.2M | $-3.6M | $-9.1M |
| EBITDA | $-686000.00 | $-686000.00 | $-318000.00 | $-1.4M | $-7.2M |
| EPS | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Gross Margin | 45.4% | 45.4% | 44.6% | 44.0% | 46.4% |
| Operating Margin | -3.3% | -3.3% | -8.9% | -21.3% | -31.1% |
| Net Margin | -21.0% | -21.0% | -17.6% | -27.7% | -96.8% |
| Balance Sheet | |||||
| Debt/Equity | -2.74 | -2.74 | -2.11 | -1.68 | -5.02 |
| Current Ratio | 0.51 | 0.51 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.9M | $1.9M | $1.1M | $-926000.00 | $-2.2M |
| Returns | |||||
| ROE | 180.0% | 180.0% | 61.8% | 93.7% | 602.8% |
| Growth & Yield | |||||
| Revenue Growth | 3.0% | 3.0% | -3.0% | 39.6% | — |
| EPS Growth | 0.0% | 0.0% | 40.0% | 61.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+0.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.00 → -0.00
Residual
+0.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.